Atossa Therapeutics examines biosecurity and scientific innovation after COVID 19 lessons

Atossa Therapeutics examines biosecurity and scientific innovation after COVID 19 lessons
Atossa Therapeutics hosts biosecurity talk

Atossa Therapeutics, Inc. is set to convene a virtual conversation on June 17 at 11:00 a.m. ET, focusing on the intersection of scientific innovation and public safety in light of recent global health crises.

The event, hosted by Demy-Colton, brings together Dr. Steven Quay and journalist Nicholas Wade to evaluate lessons learned from the COVID-19 pandemic, discuss emerging biosecurity threats, and map the future direction for the life sciences sector. The conversation aims to highlight strategies that can simultaneously foster research breakthroughs while safeguarding public health.

Atossa Therapeutics has advanced research targeting mammographic breast density as a way to lower future breast cancer risk, according to a previous company report. The company has also released findings indicating that Duchenne muscular dystrophy involves dysfunction in several biological systems, not just protein loss, as detailed in earlier disclosures. These initiatives reflect Atossa’s ongoing engagement with a range of health challenges.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.